Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,227,507

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,227,507 protect, and when does it expire?

Patent 8,227,507 protects AKLIEF and is included in one NDA.

This patent has twenty-four patent family members in twenty-one countries.

Summary for Patent: 8,227,507
Title:Ligands that modulate RAR receptors
Abstract: Novel ligand compounds having the general formula (I): ##STR00001## and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
Inventor(s): Biadatti; Thibaud (Opio, FR), Dumais; Laurence (La Rouret, FR), Soulet; Catherine (Antibes, FR), Talano; Sandrine (Vence, FR), Daver; Sebastien (Antibes, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/842,347
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,227,507

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp AKLIEF trifarotene CREAM;TOPICAL 211527-001 Oct 4, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TOPICAL TREATMENT OF ACNE VULGARIS ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,227,507

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France04 13848Dec 23, 2004

International Family Members for US Patent 8,227,507

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055297 ⤷  Try it Free
Austria 542791 ⤷  Try it Free
Australia 2005318292 ⤷  Try it Free
Brazil PI0517500 ⤷  Try it Free
Canada 2590246 ⤷  Try it Free
China 101087752 ⤷  Try it Free
Cyprus 1112721 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.